Non-parametric Bounds in Two-Sample Summary-Data Mendelian Randomization: Some Cautionary Tales for Practice

Abstract

Recently, in genetic epidemiology, Mendelian randomization (MR) has become a popular approach to estimate causal exposure effects by using single nucleotide polymorphisms from genome-wide association studies (GWAS) as instruments. The most popular type of MR study, a two-sample summary-data MR study, relies on having summary statistics from two independent GWAS and using parametric methods for estimation. However, little is understood about using a nonparametric bound-based analysis, a popular approach in traditional instrumental variables frameworks, to study causal effects in two-sample MR. In this work, we explore using a bound-based analysis in two-sample MR studies. We also propose a framework to assess how likely one can obtain more informative bounds on the causal effect if we used a different MR design, notably a one-sample MR design. We conclude by demonstrating our findings through two real data analyses concerning the causal effect of smoking on lung cancer and the causal effect of high cholesterol on heart attacks. Overall, our results suggest that while a bound-based analysis may be appealing due to its nonparametric nature, it is rarely suitable as a method of analysis to bound the causal exposure effect in two-sample MR studies unless strong assumptions are met.

1 Introduction

In recent years, genetic variants have been used as instrumental variables (IV) to estimate causal effects in epidemiological studies, often referred to as Mendelian randomization (MR) studies [17, 24, 10]. Typically, MR studies are based on a two-sample study design where published summary statistics from two independent genome wide association studies (GWAS), with one providing information about the exposure and instrument and the other about the outcome and instrument, are used [7, 11, 18]. Under a two-sample study design, investigators frequently use parametric methods to study exposure effects. Notable examples include the IVW estimator [7], MR-Egger regression [4], weighted median [5], MR-PRESSO [44] and MR-RAPS [49], to name a few; see Burgess and Thompson [10], Burgess, Small, and Thompson [8] and Slob and Burgess [38] for recent reviews.

An alternative approach to study exposure effects in instrumental variables without parametric assumptions is through nonparametric IV bounds [3, 12, 26, 31, 33]. Briefly, nonparametric IV bounds use a minimum set of assumptions to provide a range of plausible values for the exposure effect. They are typically used when the outcome, the exposure, and the instrument are all binary and are simultaneously observed; we refer to this setting as the one-sample setting to contrast it from the two-sample setting. Arguably, the most well-known IV bounds are the Balke-Pearl bounds [3] for the average treatment effect. Cheng and Small [12] and Richardson and Robins [31] extended the Balke-Pearl bounds to allow for a non-binary instrument. Ramsahai [30] derived bounds under two-sample study designs; see Swanson et al. [43] and references therein for a recent summary of IV bounds.

Using IV bounds can be an attractive alternative to study exposure effects in non-MR, one-sample settings [42, 43] and some [19, 41] have suggested using IV bounds to study exposure effects in MR studies given the strong parametric assumptions accompanying most MR analyses. Despite these suggestions, to the best of our knowledge, there is little work on using bounds in typical MR settings, i.e. two-sample study designs with summary statistics. For example, what kind of genetic variants provide the most informative conclusions about the exposure effect in terms of the bounds not containing the null effect? Can combining multiple variants lead to shorter and tighter bounds? How do the bounds change if many instruments are weak, which is typical in MR studies from two-sample designs? The overall goal of this paper is to offer some practical guidance on using IV bounds in two-sample MR studies. We focus on two aspects: (1) the length of the bounds and (2) whether bounds cover the null effect of zero, both of which inform MR investigators about the direction and relative magnitude of the exposure effect.

Our overall takeaway message for investigators using two-sample MR studies is that unless the candidate

instruments are very strong, a bound-based analysis will often be non-informative. Instead, investigators should either try to use one-sample MR studies or use well-informed parametric approaches to ascertain the exposure effect.

2 Methods

2.1 Review: Notation, Definitions, and Assumptions

Let X and Y be binary exposure and outcome variables, respectively, Z be a categorical instrumental variable taking values in $\{0, 1, 2\}$, and U be an unmeasured confounder for the effect of X on Y. Let $Y^{z,x}$ be the potential outcome [34, 39] had the subject received exposure value $X = x$ and instrument value $Z = z$. We assume the stable unit treatment value assumption (SUTVA) [16, 35], formalized as $Y = \sum_{x,z} I[Z = z, X = x] Y^{x,z}$ where $I[\cdot]$ is the indicator function.

We make the following set of assumptions about X, Y, Z, and U that are typical in MR studies; see Didelez and Sheehan [19] and Wang and Tchetgen Tchetgen [46] for details.

(A1) *(Relevance)*: $Z \not\perp X$

(A2) *(Independent instrument)*: $Z \perp U$

(A3) *(Exclusion restriction)*: $Y^{z,x} = Y^{z',x} = Y^x$ for all x, z, z'

(A4) *(Conditional ignorability of X, Z given U)*: $Y^{z,x} \perp Z, X | U$

Briefly, (A1) can be satisfied by finding SNPs that have been consistently associated with the exposure. (A2) and (A3) are justified by scientific theory and can be violated if the SNP is (i) in linkage disequilibrium with an unmeasured SNP that affects the exposure and the outcome or (ii) has multiple functions beyond affecting the exposure (i.e. pleiotropic), to name a few. Finally, (A4) states that if U is observed, then it is sufficient to unconfound the relationship between X and Y.

Throughout the paper, we will assume (A1)-(A4) hold to focus the discussion on the bounds, even though they are important to assess in practice. We make some additional remarks about assumptions (A1)-(A4). First, in practice, most MR studies only explicitly state assumptions (A1)-(A3) along with some parametric modeling assumptions [10]. Second, Richardson and Robins [31] showed that one can remove (A4) and strengthen (A2) with $Z \perp U, Y^{z,x}$ without consequence on the IV bounds. Third, under SUTVA and assumptions (A3)-(A4), we have $Y \perp Z | X, U$, which is another common way to express the exclusion

restriction in MR studies [19, 43]. Fourth, for simplicity, we do not assume the existence of a potential treatment X^z.

Next, we introduce the following assumptions (A5) and (A6); these assumptions are not necessary to construct bounds, but they will help characterize IV bounds in two-sample studies.

(A5) *(Monotonicity between Z and X)* $P(X = 1|Z = z, U) \leq P(X = 1|Z = z+1, U)$ for $z = 0, 1, 2$

(A6) *(Monotonicity between Z and Y)* $P(Y = 1|Z = z, U) \leq P(Y = 1|Z = z+1, U)$ for $z = 0, 1, 2$

A variant of (A5) is common in the IV literature to study noncompliance [1, 2]. (A6) is an extension of (A5) to the outcome variable. (A5) or (A6) is plausible in MR if the direction of the genetic instrument's effect on the exposure or the outcome is well-established from scientific theory.

We also define instrument strength ST as

$$ST = \max_{z_1 \neq z_2} |P(X = 1|Z = z_1) - P(X = 1|Z = z_2)| \tag{1}$$

ST reduces to the definition of instrument strength in Balke and Pearl [3] when the instrument is binary; Balke and Pearl [3] used ST to characterize the width of their IV bounds. Also, (1) differs from other definitions of instrument strength based on a parametric model between the exposure and the outcome, say the concentration parameter; see Stock, Wright, and Yogo [40] for an overview.

2.2 IV Bounds Under Two-Sample Designs and Goals of Paper

The most popular design in MR studies is a two-sample design which has two separate data sources, one providing information about (X, Z) in the form of $P(X = 1|Z = z)$, $z \in \{0, 1, 2\}$, and another providing information about (Y, Z) in the form of $P(Y = 1|Z = z)$, $z \in \{0, 1, 2\}$. A two-sample design differs from a more traditional one-sample design which has a single data source providing information on all observed variables (X, Y, Z) in the form of $P(Y = y, X = x|Z = z)$. IV bounds have been well-studied in one-sample designs and there is a rich array of practical guidance for practitioners interested in using them in their studies [3, 31, 43]. However, as noted in the introduction, not much is known about the behavior of IV bounds under a two-sample design, especially how (or when) MR investigators should use them in their own studies.

Formally, the goal of this paper is to offer concrete practical advice on using IV bounds to study the average treatment effect (ATE), defined as

$$\text{ATE} = E[Y^1 - Y^0] = \int P(Y = 1 \mid X = 1, U = u)P(U = u)du - \int P(Y = 1 \mid X = 0, U = u)P(U = u)du$$

based on using $P(Y = 1|Z = z)$ and $P(X = 1|Z = z)$ for each $z = 0, 1, 2$ obtained from a two-sample design. Specifically, under a two-sample design and assumptions (A1)-(A4), Ramsahai [30] derived a sharp bound for the ATE (see eAppendix A.1 for a detailed review and a discussion of "IV Inequalities" [3, 20] in two-sample MR studies).

$$\max \begin{cases} \max_{z_1 \neq z_2} & P(Y = 1|Z = z_1) - 2 \cdot P(Y = 1|Z = z_2) - 2 \cdot P(X = 1|Z = z_2) \\ \max_{z_1 \neq z_2} & P(Y = 1|Z = z_1) + P(X = 1|Z = z_1) - P(Y = 1|Z = z_2) - P(X = 1|Z = z_2) - 1 \\ \max_{z_1 \neq z_2} & 2 \cdot P(Y = 1|Z = z_1) + 2 \cdot P(X = 1|Z = z_1) - P(Y = 1|Z = z_2) - 3 \\ \max_z & -P(Y = 1|Z = z) - P(X = 1|Z = z) \\ \max_z & P(Y = 1|Z = z) + P(X = 1|Z = z) - 2 \end{cases}$$

$$\leq ATE \leq \tag{2}$$

$$\min \begin{cases} \min_{z_1 \neq z_2} & P(Y = 1|Z = z_1) - 2 \cdot P(Y = 1|Z = z_2) + 2 \cdot P(X = 1|Z = z_2) + 1 \\ \min_{z_1 \neq z_2} & P(Y = 1|Z = z_1) + 2 \cdot P(Y = 1|Z = z_2) - 2 \cdot P(X = 1|Z = z_2) + 1 \\ \min_{z_1 \neq z_2} & P(Y = 1|Z = z_1) - P(X = 1|Z = z_1) + P(X = 1|Z = z_2) - P(Y = 1|Z = z_2) + 1 \\ \min_z & P(X = 1|Z = z) - P(Y = 1|Z = z) + 1 \\ \min_z & P(Y = 1|Z = z) - P(X = 1|Z = z) + 1 \end{cases}$$

This paper studies arguably the two most relevant properties of the above bounds that can guide practice: (1) the length of the bounds and (2) the ability to obtain bounds not covering the null effect of zero. To better understand bound-specific characteristics not due to sampling errors, we will assume we have population-level quantities of $P(Y = 1|Z = z)$ and $P(X = 1|Z = z)$; in practice, these are estimated summary GWAS statistics from logistic models [24, 6, 45, 27, 23] and eAppendix A.2 contains additional details.

3 Properties of IV Bounds

3.1 Length of Bounds and Coverage of Null Effect

Theorem 3.1 characterizes the length of the IV bound in equation (2) under two-sample designs and assumptions (A1)-(A6); the extra assumptions (A5)-(A6) simplify the formula for the length of the bound to be an interpretable, linear function of instrument strength ST.

Theorem 3.1. *Under assumptions (A1)-(A6), a sharp upper bound on the length of the bound in equation (2) is $2 - 2 \cdot ST$, i.e. there exists a data generating process satisfying (A1)-(A6) and has width equal to $2 - 2 \cdot ST$.*

See eAppendix A.3 for the proof, which extends Theorem 3.1 to instruments with 2, 3, or 4 categories. Compared to the Balke-Pearl IV bounds with a binary IV in single-sample designs whose width is $1 - ST$ [3], the length of the two-sample bounds can be twice as long. Also, the length of two-sample IV bounds is only guaranteed to be less than 1 if instrument strength ST is greater than 0.5; note that this does not imply that instruments with ST less than 0.5 has length greater than 1. In contrast, one-sample IV bounds always have length less than 1 unless ST is zero. In short, there is a cost, in length, of using a two-sample design instead of a one-sample design when performing a bound-based analysis of the ATE in MR.

Figure 1A numerically illustrates the consequences of Theorem 3.1 by calculating the bounds in equation (2) from 10,000 randomly generated sets of values of $P(X = 1|Z = z)$ and $P(Y = 1|Z = z)$ that satisfy the IV inequalities and assumptions (A1)-(A4). We also use three real-world data examples where the causal effect is known to exist: the effect of high cholesterol on incidence of heart attacks [14], the effect of smoking on incidence of lung cancer [15], and the effect of obesity on incidence of heart attacks [48]. The first two studies are discussed in detail in Section 5. We see that the width of the bounds often exceed 1 as the instrument strength decreases. Also, the three real-world studies generally do not lead to bounds with length less than 1. Figure 1B further illustrates this point by characterizing the relationship between instrument strength ST and the summary statistic coefficient γ_1 from a logistic exposure model $\text{logit}(P(X = 1|Z = z, U = u)) = \gamma_0 + \gamma_1 z + \gamma_U u$ commonly used in parametric approaches to analyzing two-sample MR studies; see eAppendix A.4 for details. We see that instrument strength ST of 0.5 corresponds to a regression coefficient γ_1 of approximately $1.1, 1.16, 1.4$ and 1.8 if γ_U is $0.1, 0.5, 1$ and 2, respectively. Coefficients with such magnitudes are rare in GWAS where genetic variants often explain a small amount of variation in the exposure. To better contextualize this observation, we note that these values of γ_1 correspond to odds ratios between 3 and 6 whereas the strong causal effect of exposure to ultraviolet light

on the incidence of skin cancer is estimated be in the range from 1.4 to 2.22 [36].

A

B

Figure 1: Illustration of the relationship between instrument strength, width of bounds obtained from two-sample design, and coefficients from logistic regression model. A: Relationship between instrument strength (ST) and width of the IV bounds. Black line is the upper bound on the two-sample IV bounds from Theorem 1. Black dots indicate one of the 10,000 IV bounds. Colored dots indicate bounds from real data; see Section 5 for details. B: Coefficients from logistic regression model and instrument strength (ST).

Next, for bounds with length less than 1, we examine what kind of γ_1 is needed in order for the two-sample IV bounds to exclude 0 for an anticipated effect size of the ATE. This question is akin to computing the power of bounds but with population-level quantities. We reuse the same logistic model above for the exposure and the outcome; see eAppendix A.4 for details on this setup. Figure 2 shows the smallest γ_1 needed to exclude 0 for different values of the ATE. Even for moderate effect sizes of 0.4, the corresponding γ_1 must be around 2, a tall order for most GWAS. Also, as the effect of unmeasured confounding increases via γ_U, a larger γ_1 is needed to exclude 0.

Figure 2: The smallest γ_1 needed for a two-sample IV bound to exclude 0.

Overall, using two-sample MR studies with a bound-based analysis is unlikely to be informative. The bounds will often have length greater than 1 and rarely exclude 0 unless very strong genetic variants are used.

3.2 Would Multiple Instruments Help?

Based on the results above with a single instrument, a natural question from investigators is whether using multiple instruments can lead to more informative bounds for the ATE; see Swanson [41] for a recent discussion on this point. For example, suppose we aggregate two-sample IV bounds across multiple instruments by taking intersections of individual IV bounds. This approach may be inferior to another alternative where we expand the levels of Z from $0, 1, 2$ to accommodate multiple instruments [41], but has the benefit of being applicable to most two-sample MR studies. However, as we show in eAppendix A.5, the strongest instrument essentially determines the length of the intersection bound because the bounds from each instrument exhibit a nesting property. In short, using a bound based on the strong instrument provides the same amount of information about the ATE as the intersection of individual IV bounds from multiple instruments.

4 Charactering the Loss of Information in Two-Sample MR Studies

As hinted in Theorem 3.1, the increase in the bound's length is an inevitable "cost" of using two-sample designs instead of one-sample designs in MR studies. This section investigates this loss of information in a bit more detail by creating a plausible range of the joint distribution of the outcome and the exposure given the instrument, $P(X = x, Y = y | Z = z)$, based on the observed data from two-sample MR studies. Specifically, using $P(X = x | Z = z)$ and $P(Y = y | Z = z)$, and a uniform prior over the values of the unknown quantities $\text{Cov}(X = x, Y = y | Z = z)$ that make up a joint distribution $P(X, Y | Z)$ which satisfy the IV assumptions, we compute $P(X = x, Y = y | Z = z)$ and its corresponding one-sample IV bounds of Balke and Pearl [3] and Richardson and Robins [31]; see eAppendix A.6 for details and also the connection to empirical Bayesian frameworks. If a large number of the one-sample IV bounds obtained from this procedure do not cover zero, then there is some evidence for a non-zero exposure effect and a one-sample MR study may yield informative bounds on the ATE. However, if a large number of the one-sample IV bounds cover zero, there is little hope of obtaining information about the ATE from bound-based approaches even if we used a one-sample MR design; in other words, the one-sample IV bounds are likely as conservative as the two-sample IV bounds.

Table 1 presents nine different sets of values of the marginal distributions $P(Y|Z)$ and $P(X|Z)$ that investigators could theoretically obtain from hypothetical two-sample MR studies. Figure 3 shows the one-sample IV bounds from the procedure we illustrated above.

Table 1: Values of $P(X = 1 | Z = z)$ and $P(Y = 1 | Z = z)$ used to illustrate our approach. For each cell (e.g. row A, column 1), we have $\{P(X = 1 | Z = 0), P(X = 1 | Z = 1), P(X = 1 | Z = 2)\}$ on the first row and $\{P(Y = 1 | Z = 0), P(Y = 1 | Z = 1), P(Y = 1 | Z = 2)\}$ on the second row.

|	Column 1	Column 2	Column 3
Row A	{0.125, 0.399, 0.080}	{0.244, 0.275, 0.185}	{0.603, 0.469, 0.310}
	{0.699, 0.840, 0.742}	{0.238, 0.089, 0.146}	{0.638, 0.346, 0.719}
Row B	{0.886, 0.968, 0.874}	{0.139, 0.441, 0.334}	{0.901, 0.909, 0.935}
	{0.805, 0.822, 0.951}	{0.179, 0.359, 0.559}	{0.821, 0.810, 0.905}
Row C	{0.175, 0.079, 0.365}	{0.493, 0.911, 0.085}	{0.434, 0.045, 0.733}
	{0.599, 0.358, 0.087}	{0.360, 0.480, 0.441}	{0.747, 0.370, 0.169}

Figure 3: One-sample bounds (horizontal lines) and two-sample bounds (vertical dotted lines). Red color represents one-sample bounds that do not cover zero and gray color represents one-sample bounds that do cover zero.

Row A of Figure 3 shows three scenarios where the two-sample bounds are all centered close to zero with similar widths. But, the conclusions from the one-sample bound analysis are rather different. Column 1 shows no one-sample bounds would allow us to determine the presence of a non-zero exposure effect. Column 2 indicates that about 26.3% of the one-sample IV bounds does not contain 0 while for column 3 that number is approximately 35.9%. However, the latter includes one-sample bounds entirely below 0 and one-sample

bounds entirely above 0.

Row B illustrates three scenarios where the two-sample bounds are centered well above zero and have large widths. We see one case where we have no hope of determining direction of the ATE from the one-sample bounds (column 1), one case where we are most likely to determine the ATE's direction (column 2), and one case where we are unlikely to determine the ATE's direction (column 3).

Row C is similar to row A in that all the two-sample bounds are centered around 0, but the widths of the two-sample bounds are narrow. The three columns indicate similar conclusions as row A, showing that even with rather narrow two-sample bounds centered around 0, the one-sample bounds may still reveal some information about presence as well as the direction of the exposure effect.

Overall, our results above show that some two-sample MR studies could potentially reveal something useful about the ATE had we used a one-sample design. Nevertheless, we mention a word of caution when interpreting the results above, especially concerning the flat prior on the covariances. For example, a scenario like the one resulting in the bounds presented in row B, column 2 only provides honest information about the one-sample bounds if our prior on $\text{Cov}(X, Y | Z)$ is correctly specified. If the prior is mis-specified whereby most one-sample bounds cover negative values of the ATE, a negative value of the ATE is possible. But in this case, if the ATE is in fact negative, our method does rule out the possibility of one-sample bounds being able to ascertain this because all one-sample bounds covering a negative ATE also covers 0.

5 Using Bound-Based Analysis in Two, Positive Control Examples

We demonstrate our findings about the behavior of two-sample IV bounds on two real MR studies. Our first study examines the effect of smoking on incidence of lung cancer and our second study examines the effect of self-reported high cholesterol on incidence of heart attack. The effect of smoking on lung cancer is known to be strong and positive [29]. Also, while the exact mechanism between high cholesterol and heart disease is still being discussed [22, 32], some meta-analyses of randomized clinical trials of the effect of cholesterol-lowering medication suggest a strong causal relationship [13, 14]. In both cases, we assess what conclusions are attainable based on bound-based analyses in studies where the causal effects are known to be strong and positive.

The study data were obtained from the UK Biobank data stored in the Integrative Epidemiology Unit (IEU) GWAS database. Specifically, data on smoking was obtained from the data entry ID ukb-d-20116_0, data

on lung cancer was from data entry ID ukb-d-40001_C349, data on cholesterol was from data entry ID ukb-a-108, and data on heart attack was from data entry ID ukb-a-434. We use the `TwoSampleMR` R package [21] with the recommended defaults to extract and clean the data. For more details, see eAppendix A.7.

For the effect of smoking on lung cancer, we used 84 genetic instruments, and for the effect of cholesterol on heart attack, we used 54 genetic instruments. The average instrument strengths were 0.0042 (range: 0.0032 to 0.0091) for smoking and 0.0005 (range: 0.0002 to 0.0022) for cholesterol; these values are much smaller than the ST = 0.5 needed to guarantee narrow bounds. As such, the two-sample bounds in Figure 4 are rather wide; all of them have width greater than 1 and they convey no information about the causal effects of interest. Additionally, using our method from Section 4, the direction of the ATE may be difficult to determine had we had one-sample IV bounds; see Figure 5. eAppendix A.7 contains additional analysis, notably demonstrating that aggregating multiple bounds through intersections are also non-informative.


Figure 4: Two-sample IV bounds for the two real data examples with 8 SNPs from each data set. A: Two-sample IV bounds for the ATE of smoking on the incidence of lung cancer. B: Two-sample IV bounds for the ATE of high cholesterol on the incidence of heart attack.

Overall, while nonparametric bounds allow us to not make parametric assumptions frequent in two-sample MR analyses, they may be too conservative and provide little, if any, information about the exposure effects, even if the exposure effect is known to be positive and strong. Additionally, since many MR studies involve weak instruments, we believe bound-based approaches will likely have limited practical value to uncover causal effects.

**A**   **B**

Figure 5: Potential one-sample IV bounds for the two real data examples using the method described in Section 4. A: One-sample IV bounds for the ATE of smoking on the incidence of lung cancer from 500 potential one-sample distributions for each SNP. B: One-sample IV bounds for the ATE of high cholesterol on the incidence of heart attack from 500 potential one-sample distributions for each SNP.

13

6   Discussion

Nonparametric bounds are without a doubt an attractive concept. With a minimal set of assumptions, they let investigators obtain bounds on the average treatment effect. However, as we have seen above, in typical MR studies with two-sample summary data, a bound-based analysis may generally be uninformative for two reasons. First, while IV bounds in one-sample settings have length always less than 1, in two-sample settings, this is not always the case. Second, many genetic variants in MR studies are too weakly associated with the exposure to produce bounds with length less than 1 or bounds that exclude 0. Indeed, our two real data examples showed that despite having strong causal effects, bound-based analyses were unable to detect these effects.

We also outlined an approach to roughly quantify the information loss going from one-sample designs to two-sample designs and to assess the range of conclusions that can be drawn from bound-based approaches if we had one-sample data. We demonstrate our method to a few different settings of two-sample data and showed the range of conclusions that can be drawn about the ATE.

What do our results suggest for bound-based analysis in two-sample MR settings in practice? Overall, our general recommendation is that unless investigators have a very strong instrument, ideally exceeding $ST > 0.5$, bounds will unlikely be useful as a nonparametric analysis of the ATE. Even if $ST > 0.5$, one would need strong IVs and/or strong effect sizes to make sure that the bounds do not cover 0. Indeed, in most cases, we believe investigators should use well-informed parametric methods to analyze the ATE. Nevertheless, there may be few limited, but meaningful use cases for bounds in two-sample MR studies. First when one has prior knowledge about the direction of the effect, but wish to get a better sense of the magnitude, nonparametric bounds can provide an upper limit on this magnitude. This is especially useful in cases where the exposure is known to cause harm or benefit, for example in our smoking on lung cancer example where the direction of the effect of smoking on lung cancer is well known and an upper bound on this effect would tell investigators about the maximum possible effect that smoking could have on increasing the incidence of lung cancer. Second, two-sample IV bounds can be used to check estimates from parametric methods to see if they lie inside of the bounds; if the estimates lie outside of the bounds, then the parametric models underlying the estimates are likely mis-specified.

References

[1] Joshua D. Angrist, Guido W. Imbens, and Donald B. Rubin. "Identification of Causal Effects Using Instrumental Variables". In: *Journal of the American Statistical Association* 91.434 (1996), pp. 444–455. ISSN: 0162-1459. DOI: 10.2307/2291629.

[2] Michael Baiocchi, Jing Cheng, and Dylan S. Small. "Instrumental Variable Methods for Causal Inference: Instrumental Variable Methods for Causal Inference". en. In: *Statistics in Medicine* 33.13 (June 2014), pp. 2297–2340. ISSN: 02776715. DOI: 10.1002/sim.6128.

[3] Alexander Balke and Judea Pearl. "Bounds on Treatment Effects from Studies with Imperfect Compliance". In: *Journal of the American Statistical Association* 92.439 (Sept. 1, 1997), pp. 1171–1176. ISSN: 0162-1459. DOI: 10.1080/01621459.1997.10474074. URL: https://doi.org/10.1080/01621459.1997.10474074 (visited on 02/05/2020).

[4] Jack Bowden et al. "Assessing the Suitability of Summary Data for Two-Sample Mendelian Randomization Analyses Using MR-Egger Regression: The Role of the I2 Statistic". en. In: *International Journal of Epidemiology* 45.6 (Dec. 2016), pp. 1961–1974. ISSN: 0300-5771. DOI: 10.1093/ije/dyw220.

[5] Jack Bowden et al. "Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator". eng. In: *Genetic Epidemiology* 40.4 (May 2016), pp. 304–314. ISSN: 1098-2272. DOI: 10.1002/gepi.21965.

[6] Stephen Burgess. "Sample Size and Power Calculations in Mendelian Randomization with a Single Instrumental Variable and a Binary Outcome". In: *International Journal of Epidemiology* 43.3 (June 1, 2014), pp. 922–929. ISSN: 0300-5771. DOI: 10.1093/ije/dyu005. URL: https://academic.oup.com/ije/article/43/3/922/761826 (visited on 11/22/2020).

[7] Stephen Burgess, Adam Butterworth, and Simon G. Thompson. "Mendelian Randomization Analysis with Multiple Genetic Variants Using Summarized Data". eng. In: *Genetic Epidemiology* 37.7 (Nov. 2013), pp. 658–665. ISSN: 1098-2272. DOI: 10.1002/gepi.21758.

[8] Stephen Burgess, Dylan S Small, and Simon G Thompson. "A Review of Instrumental Variable Estimators for Mendelian Randomization". en. In: *Statistical Methods in Medical Research* 26.5 (Oct. 2017), pp. 2333–2355. ISSN: 0962-2802. DOI: 10.1177/0962280215597579.

[9] Stephen Burgess and Simon G. Thompson. "Improving Bias and Coverage in Instrumental Variable Analysis with Weak Instruments for Continuous and Binary Outcomes". In: *Statistics in Medicine* 31.15 (2012), pp. 1582–1600. ISSN: 1097-0258. DOI: 10.1002/sim.4498. URL: https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.4498 (visited on 11/29/2020).

[10] Stephen Burgess and Simon G. Thompson. *Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation*. English. 1st edition. Boca Raton: Chapman and Hall/CRC, Mar. 2015. ISBN: 978-1-4665-7317-8.

[11] Stephen Burgess et al. "Using Published Data in Mendelian Randomization: A Blueprint for Efficient Identification of Causal Risk Factors". eng. In: *European Journal of Epidemiology* 30.7 (July 2015), pp. 543–552. ISSN: 1573-7284. DOI: 10.1007/s10654-015-0011-z.

[12] Jing Cheng and Dylan S. Small. "Bounds on Causal Effects in Three-Arm Trials with Non-Compliance". In: *Journal of the Royal Statistical Society. Series B (Statistical Methodology)* 68.5 (2006), pp. 815–836. ISSN: 1369-7412.

[13] Cholesterol Treatment Trialists' (CTT) Collaborators. "Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90 056 Participants in 14 Randomised Trials of Statins". In: *The Lancet* 366.9493 (2005), pp. 1267–1278. ISSN: 0140-6736. DOI: 10.1016/S0140-6736(05)67394-1. URL: http://www.sciencedirect.com/science/article/pii/S0140673605673941.

[14] Cholesterol Treatment Trialists' (CTT) Collaborators. "The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials". In: *The Lancet* 380.9841 (Aug. 2012), pp. 581–590. ISSN: 01406736. DOI: 10.1016/S0140-6736(12)60367-5. URL: https://linkinghub.elsevier.com/retrieve/pii/S0140673612603675 (visited on 12/03/2020).

[15] Jerome Cornfield et al. "Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions". en. In: *JNCI: Journal of the National Cancer Institute* 22.1 (Jan. 1959), pp. 173–203. ISSN: 0027-8874. DOI: 10.1093/jnci/22.1.173.

[16] D. R. Cox. *Planning of Experiments*. Planning of Experiments. Oxford, England: Wiley, 1958, p. 308.

[17] George Davey Smith and Shah Ebrahim. "'Mendelian Randomization': Can Genetic Epidemiology Contribute to Understanding Environmental Determinants of Disease?" en. In: *International Journal of Epidemiology* 32.1 (Feb. 2003), pp. 1–22. ISSN: 0300-5771. DOI: 10.1093/ije/dyg070.

[18] Neil M. Davies, Michael V. Holmes, and George Davey Smith. "Reading Mendelian Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians". en. In: *BMJ* 362 (July 2018). ISSN: 0959-8138, 1756-1833. DOI: 10.1136/bmj.k601.

[19] Vanessa Didelez and Nuala Sheehan. "Mendelian Randomization as an Instrumental Variable Approach to Causal Inference". eng. In: *Statistical Methods in Medical Research* 16.4 (Aug. 2007), pp. 309–330. ISSN: 0962-2802. DOI: 10.1177/0962280206077743.

[20] Elizabeth W. Diemer et al. "Application of the Instrumental Inequalities to a Mendelian Randomization Study With Multiple Proposed Instruments". en-US. In: *Epidemiology* 31.1 (Jan. 2020), p. 65. ISSN: 1044-3983. DOI: 10.1097/EDE.0000000000001126.

[21] Gibran Hemani et al. "The MR-Base platform supports systematic causal inference across the human phenome". In: *eLife* 7 (May 2018). Ed. by Ruth Loos, e34408. ISSN: 2050-084X. DOI: 10.7554/eLife.34408. URL: https://doi.org/10.7554/eLife.34408.

[22] Michael V. Holmes et al. "Mendelian Randomization of Blood Lipids for Coronary Heart Disease". In: *European Heart Journal* 36.9 (Mar. 1, 2015), pp. 539–550. ISSN: 1522-9645, 0195-668X. DOI: 10.1093/eurheartj/eht571. URL: https://academic.oup.com/eurheartj/article/36/9/539/506920 (visited on 12/03/2020).

[23] Catherine King et al. "Mendelian Randomization Case-Control PheWAS in UK Biobank Shows Evidence of Causality for Smoking Intensity in 28 Distinct Clinical Conditions". In: *EClinicalMedicine* 26 (Sept. 1, 2020). ISSN: 2589-5370. DOI: 10.1016/j.eclinm.2020.100488. URL: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30232-7/abstract (visited on 11/22/2020).

[24] Debbie A. Lawlor et al. "Mendelian Randomization: Using Genes as Instruments for Making Causal Inferences in Epidemiology". eng. In: *Statistics in Medicine* 27.8 (Apr. 2008), pp. 1133–1163. ISSN: 0277-6715. DOI: 10.1002/sim.3034.

[25] Po-Ru Loh et al. "Contrasting Genetic Architectures of Schizophrenia and Other Complex Diseases Using Fast Variance-Components Analysis". In: *Nature Genetics* 47.12 (Dec. 2015), pp. 1385–1392. ISSN: 1546-1718. DOI: 10.1038/ng.3431. pmid: 26523775.

[26] Charles F. Manski. "Nonparametric Bounds on Treatment Effects". In: *The American Economic Review* 80.2 (1990), pp. 319–323. ISSN: 0002-8282.

[27] Louise A. C. Millard et al. "MR-pheWAS with Stratification and Interaction: Searching for the Causal Effects of Smoking Heaviness Identified an Effect on Facial Aging". In: *PLOS Genetics* 15.10 (Oct. 31, 2019), e1008353. ISSN: 1553-7404. DOI: 10.1371/journal.pgen.1008353. URL: https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1008353 (visited on 11/22/2020).

[28] Timpson Nj et al. "Genetic Architecture: The Shape of the Genetic Contribution to Human Traits and Disease." In: *Nature reviews. Genetics* 19.2 (Dec. 11, 2017), pp. 110–124. ISSN: 1471-0056, 1471-0064. DOI: 10.1038/nrg.2017.101. pmid: 29225335. URL: http://europepmc.org/article/MED/29225335 (visited on 11/29/2020).

[29] Surgeon General's Advisory Committee on Smoking and ealth, United States. *Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service.* Public Health Service Publication. U.S. Department of Health, Education, and Welfare, Public Health Service, 1964. URL: https://books.google.com/books?id=yPtqAAAAMAAJ.

[30] Roland R. Ramsahai. "Causal Bounds and Observable Constraints for Non-Deterministic Models". In: *J. Mach. Learn. Res.* 13 (Mar. 2012), pp. 829–848. ISSN: 1532-4435.

[31] Thomas S. Richardson and James M. Robins. "ACE Bounds; SEMs with Equilibrium Conditions". In: *Statistical Science* 29.3 (Aug. 2014), pp. 363–366. ISSN: 0883-4237. DOI: 10.1214/14-STS485. arXiv: 1410.0470.

[32] Tom G. Richardson et al. "Evaluating the Relationship between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart Disease: A Multivariable Mendelian Randomisation Analysis". In: *PLOS Medicine* 17.3 (Mar. 23, 2020). Ed. by Daniel J. Rader, e1003062. ISSN: 1549-1676. DOI: 10.1371/journal.pmed.1003062. URL: https://dx.plos.org/10.1371/journal.pmed.1003062 (visited on 12/03/2020).

[33] James M Robins. "The Analysis of Randomized and Nonrandomized AIDS Treatment Trials Using A New Approach to Causal Inference in Longitudinal Studies". In: *Health Service Research Methodology: A Focus On AIDS* (1989), pp. 113–159.

[34] Donald B. Rubin. "Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies." en. In: *Journal of Educational Psychology* 66.5 (1974), pp. 688–701. ISSN: 0022-0663. DOI: 10.1037/h0037350.

[35] Donald B. Rubin. "Randomization Analysis of Experimental Data: The Fisher Randomization Test Comment". In: *Journal of the American Statistical Association* 75.371 (1980), pp. 591–593. ISSN: 0162-1459. DOI: 10.2307/2287653.

[36] J. Schmitt et al. "Occupational Ultraviolet Light Exposure Increases the Risk for the Development of Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis". In: *The British Journal of Dermatology* 164.2 (Feb. 2011), pp. 291–307. ISSN: 1365-2133. DOI: 10.1111/j.1365-2133.2010.10118.x. pmid: 21054335.

[37] Huwenbo Shi, Gleb Kichaev, and Bogdan Pasaniuc. "Contrasting the Genetic Architecture of 30 Complex Traits from Summary Association Data". In: *The American Journal of Human Genetics* 99.1 (July 7, 2016), pp. 139–153. ISSN: 0002-9297. DOI: 10.1016/j.ajhg.2016.05.013. URL: http://www.sciencedirect.com/science/article/pii/S0002929716301483 (visited on 11/29/2020).

[38] Eric A. W. Slob and Stephen Burgess. "A Comparison of Robust Mendelian Randomization Methods Using Summary Data". In: *Genetic Epidemiology* 44.4 (2020), pp. 313–329. ISSN: 1098-2272. DOI: 10.1002/gepi.22295. URL: https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.22295 (visited on 12/08/2020).

[39] Jerzy Splawa-Neyman. "On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9." Trans. by D. M. Dabrowska and T. P. Speed. In: *Statistical Science* 5.4 (1923). Translated in 1990., pp. 465–472. ISSN: 0883-4237.

[40] James H Stock, Jonathan H Wright, and Motohiro Yogo. "A Survey of Weak Instruments and Weak Identification in Generalized Method of Moments". In: *Journal of Business & Economic Statistics* 20.4 (Oct. 2002), pp. 518–529. ISSN: 0735-0015. DOI: 10.1198/073500102288618658.

[41] Sonja A. Swanson. "Commentary: Can We See the Forest for the IVs? Mendelian Randomization Studies with Multiple Genetic Variants". In: *Epidemiology* 28.1 (Jan. 2017), pp. 43–46. ISSN: 1044-3983. DOI: 10.1097/EDE.0000000000000558. URL: https://journals.lww.com/00001648-201701000-00007 (visited on 12/01/2020).

[42] Sonja A. Swanson and Miguel A. Hernán. "Commentary: How to Report Instrumental Variable Analyses (Suggestions Welcome)". In: *Epidemiology* 24.3 (May 2013), pp. 370–374. ISSN: 1044-3983. DOI: 10.1097/EDE.0b013e31828d0590.

[43] Sonja A. Swanson et al. "Partial Identification of the Average Treatment Effect Using Instrumental Variables: Review of Methods for Binary Instruments, Treatments, and Outcomes". en. In: *Journal of the American Statistical Association* 113.522 (Apr. 2018), pp. 933–947. ISSN: 0162-1459, 1537-274X. DOI: 10.1080/01621459.2018.1434530.

[44] Marie Verbanck et al. "Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian Randomization between Complex Traits and Diseases". In: *Nature Genetics* 50.5 (May 2018), pp. 693–698. ISSN: 1061-4036, 1546-1718. DOI: 10.1038/s41588-018-0099-7. URL: http://www.nature.com/articles/s41588-018-0099-7 (visited on 12/08/2020).

[45] Anurag Verma et al. "A Simulation Study Investigating Power Estimates in Phenome-Wide Association Studies". In: *BMC Bioinformatics* 19.1 (Apr. 4, 2018), p. 120. ISSN: 1471-2105. DOI: 10.1186/s12859-018-2135-0. URL: https://doi.org/10.1186/s12859-018-2135-0 (visited on 11/22/2020).

[46] Linbo Wang and Eric Tchetgen Tchetgen. *Bounded, Efficient and Multiply Robust Estimation of Average Treatment Effects Using Instrumental Variables*. Jan. 4, 2018. arXiv: 1611.09925 [stat]. URL: http://arxiv.org/abs/1611.09925 (visited on 11/09/2020).

[47]   Jian Yang et al. "Common SNPs Explain a Large Proportion of the Heritability for Human Height". In: *Nature Genetics* 42.7 (July 2010), pp. 565–569. ISSN: 1546-1718. DOI: 10.1038/ng.608. pmid: 20562875.

[48]   Salim Yusuf et al. "Obesity and the Risk of Myocardial Infarction in 27,000 Participants from 52 Countries: A Case-Control Study". In: *Lancet (London, England)* 366.9497 (Nov. 5, 2005), pp. 1640–1649. ISSN: 1474-547X. DOI: 10.1016/S0140-6736(05)67663-5. pmid: 16271645.

[49]   Qingyuan Zhao et al. "Statistical Inference in Two-Sample Summary-Data Mendelian Randomization Using Robust Adjusted Profile Score". EN. In: *Annals of Statistics* 48.3 (June 2020), pp. 1742–1769. ISSN: 0090-5364, 2168-8966. DOI: 10.1214/19-AOS1866.